Evaluation of the Neutrophil-Based Inflammatory Indexes SIRI and NHR in Patients with Extensive-Stage Small Cell Lung Cancer Receiving First-Line Immune Checkpoint Inhibitors Plus Chemotherapy.

The baseline serum SIRI and NHR can serve as promising indicators of prognosis, but not treatment response, in ES-SCLC patients receiving first-line ICIs and chemotherapy.